Lovely Goyal

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

Background First-line treatment options are limited for patients with advanced cholangiocarcinoma (CCA). Genetic alterations in the fibroblast growth factor receptor (FG...

Teresa Macarulla , MD, PhD;

Sudipta Roychowdhury , MD;

R. Shroff ;

J. Soto ;

G. Pedrioli ;

L. Fumagalli ;

C. dambkowski ;

M. Javle ;

Ghassan Abou-Alfa , MD, MBA;

D. Oh ;

I. Borbath ;

Lovely Goyal ;

Angela Lamarca , MD, PhD, MSc;

06/27/2022

ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma

Purpose of the Study: Patients with large B cell lymphoma (LBCL) who have persistent disease assessed by dynamic positron emission tomography after rituximab-based induction therapy have ...

Jun Kawashima ;

Alex F. Herrera ;

Sven de Vos , MD, PhD;

Sattva S. Neelapu ;

Julio C. Chavez ;

Yi Lin ;

Javier Munoz ;

Lovely Goyal ;

Chaitra S. Ujjani ;

Peter Riedell ;

Olalekan O. Oluwole ;

Natasha Kekre ;